ProQR Therapeutics (PRQR) Short term Debt (2013 - 2026)
ProQR Therapeutics (PRQR) posted Short term Debt of $5.8 million for Q1 2026, up 2.08% sequentially from $5.7 million in Q4 2025, and up 18.23% YoY from $4.9 million in Q1 2025.
ProQR Therapeutics (PRQR) Short term Debt (2013 - 2026) Analysis & Trends
ProQR Therapeutics has reported Short term Debt for 14 years, with the latest figure at $5.8 million in Q1 2026.
- Quarterly Short term Debt rose 18.23% year-over-year to $5.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.8 million (up 18.23% YoY) and the FY2025 annual result came in at $5.7 million, up 15.83% from the prior year.
- Short term Debt advanced to $5.8 million in Q1 2026 per PRQR's latest filing, from $5.7 million in the prior quarter.
- Over five years, Short term Debt peaked at $43.1 million in Q1 2022 and troughed at $2.6 million in Q4 2022.
- A 5-year average of $9.3 million and a median of $4.9 million in 2025 frame the typical range for Short term Debt.
- The sharpest annual moves came in 2022 and 2023: Short term Debt soared 216181.09% in 2022, then plunged 90.34% in 2023.
- Over 5 years, Short term Debt stood at $2.6 million in 2022, then gained by 23.39% to $3.1 million in 2023, then soared by 55.58% to $4.9 million in 2024, then advanced by 15.83% to $5.7 million in 2025, then advanced by 2.08% to $5.8 million in 2026.
- According to Business Quant data, Short term Debt over the past three periods registered $5.8 million, $5.7 million, and $5.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | ProQR Therapeutics | 206.80 Mn | 111.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.79 Mn |
| Dec 31, 2025 | 5.67 Mn |
| Sep 30, 2025 | 5.61 Mn |
| Jun 30, 2025 | 5.35 Mn |
| Mar 31, 2025 | 4.90 Mn |
| Dec 31, 2024 | 4.90 Mn |
| Sep 30, 2024 | 4.95 Mn |
| Jun 30, 2024 | 4.78 Mn |
| Mar 31, 2024 | 4.74 Mn |
| Sep 30, 2023 | 3.15 Mn |
| Jun 30, 2023 | 3.89 Mn |
| Mar 31, 2023 | 4.19 Mn |
| Dec 31, 2022 | 2.55 Mn |
| Sep 30, 2022 | 4.81 Mn |
| Jun 30, 2022 | 40.31 Mn |
| Mar 31, 2022 | 43.06 Mn |
| Dec 31, 2021 | 5.46 Mn |
| Sep 30, 2021 | 20.65 Mn |
| Jun 30, 2021 | 20.44 Mn |
| Mar 31, 2021 | 19,910.13 |